Paul Jung
YOU?
Author Swipe
View article: Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis
Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis Open
Genetic abnormalities in multiple myeloma (MM) influence treatment outcomes and may inform therapeutic decisions. The most common chromosomal translocation in MM is t(11;14); however, its role in disease progression is not well defined. We…
View article: Identification of Novel Nexilin Splice Variants in Mouse and Human Tissues
Identification of Novel Nexilin Splice Variants in Mouse and Human Tissues Open
There is no doubt that the proper development of the heart is important for its correct function, in addition, maturation processes of the heart are crucial as well. The actin-binding protein nexilin seems to take over central roles in the…
View article: Supplementary Figure 3 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 3 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Efficacy of ABBV-MALT1 the OCI-LY10 CDX model
View article: Data from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Data from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
The activated B cell (ABC) subset of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic B-cell receptor signaling and associated with poor outcomes when treated with standard therapy. In ABC-DLBCL, MALT1 is a core enzyme tha…
View article: Supplementary Figure 4 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 4 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Efficacy of ABBV-MALT1 across non-GCB PDX models
View article: Supplementary Materials and Methods from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Materials and Methods from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Supplementary Materials and Methods
View article: Supplementary Materials and Methods from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Materials and Methods from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Supplementary Materials and Methods
View article: Supplementary File 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary File 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Excel Workbook ABBV-MALT1 Pharmacology
View article: Supplementary Figure 6 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 6 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
In vitro and in vivo combination of ABBV-MALT1 and venetoclax
View article: Supplementary Figure 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Whole proteomic analysis of ABBV-MALT1 in OCI-LY3
View article: Supplementary Figure 6 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 6 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
In vitro and in vivo combination of ABBV-MALT1 and venetoclax
View article: Supplementary Figure 5 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 5 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Antiapoptotic complex formation in ABC-DLBCL xenografts after ABBV-MALT1 monotherapy
View article: Supplementary Figure 7 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 7 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
MALT1 and BCL2 inhibition do not antagonize each other in monotherapy sensitive patient derived xenografts
View article: Supplementary Figure 7 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 7 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
MALT1 and BCL2 inhibition do not antagonize each other in monotherapy sensitive patient derived xenografts
View article: Supplementary Figure 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Pan-lineage PRISM analysis of ABBV-MALT1 sensitivity.
View article: Supplementary Figure 3 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 3 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Efficacy of ABBV-MALT1 the OCI-LY10 CDX model
View article: Supplementary Figure 5 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 5 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Antiapoptotic complex formation in ABC-DLBCL xenografts after ABBV-MALT1 monotherapy
View article: Supplementary Figure 4 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 4 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Efficacy of ABBV-MALT1 across non-GCB PDX models
View article: Data from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Data from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
The activated B cell (ABC) subset of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic B-cell receptor signaling and associated with poor outcomes when treated with standard therapy. In ABC-DLBCL, MALT1 is a core enzyme tha…
View article: Supplementary Figure 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Pan-lineage PRISM analysis of ABBV-MALT1 sensitivity.
View article: Supplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Excel Workbook RNASeq
View article: Supplementary File 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary File 1 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Excel Workbook ABBV-MALT1 Pharmacology
View article: Supplementary Figure 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary Figure 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Whole proteomic analysis of ABBV-MALT1 in OCI-LY3
View article: Supplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Supplementary File 2 from Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
Excel Workbook RNASeq
View article: Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma
Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma Open
The activated B cell (ABC) subset of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic B-cell receptor signaling and associated with poor outcomes when treated with standard therapy. In ABC-DLBCL, MALT1 is a core enzyme tha…
View article: AML-095 Findings From an Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia (AML), Including AML-M4 and AML-M5, Treated With Venetoclax (Ven) Plus Azacitidine (Aza)
AML-095 Findings From an Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia (AML), Including AML-M4 and AML-M5, Treated With Venetoclax (Ven) Plus Azacitidine (Aza) Open
View article: POSTER: AML-095 Findings From an Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia (AML), Including AML-M4 and AML-M5, Treated With Venetoclax (Ven) Plus Azacitidine (Aza)
POSTER: AML-095 Findings From an Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia (AML), Including AML-M4 and AML-M5, Treated With Venetoclax (Ven) Plus Azacitidine (Aza) Open
View article: P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE
P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE Open
Background: Venetoclax (ven) in combination with hypomethylating agents or low dose cytarabine leads to rapid and durable remission in patients (pts) with acute myeloid leukemia (AML) unfit for intensive chemotherapy (IC), however, pts wit…
View article: P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA) Open
Background: Ven+Aza has shown efficacy in patients (pts) with AML ineligible for intensive chemotherapy (IC). In monocytic AML (mAML), ex vivo studies have shown that Ven may have reduced activity secondary to overexpression of MCL1 (Kuusa…
View article: MALT1 protease inhibition overcomes BTK inhibitor resistance and shows synergistic activity with venetoclax in models of B cell lymphoma and leukemia
MALT1 protease inhibition overcomes BTK inhibitor resistance and shows synergistic activity with venetoclax in models of B cell lymphoma and leukemia Open
Introduction: Specific B cell malignancies, including CLL and the aggressive non-GCB subtype of DLBCL, are driven by constitutive activation of the B cell receptor (BCR) pathway and the transcription factor NF-κB. Pharmacological inhibitio…